We scoured the nation to identify the best stock in every state. Intercept Pharmaceuticals (symbol ICPT) is the publicly traded company we picked in New York. The company headquarters is located in New York City.
A word of caution: Since we selected a single stock from each state (plus one from D.C), and choices in some states are sparse, a few of our picks are best suited to investors comfortable with a higher degree of risk. This is not necessarily one of our 51 favorite stocks in the entire U.S., in other words.
Intercept Pharmaceuticals by the Numbers
- Headquarters: New York City
- Share price: $130.57
- Market value: $3.3 billion
- Price-earnings ratio: NA
(Prices and data are as of June 22, 2017)
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Intercept is a biotech company focused on treatments for liver diseases. The company celebrated its first major victory last year when its key drug, Ocaliva, received FDA approval to treat primary biliary cholangitis, a rare liver disease that affects a person’s bile ducts. The drug is the first commercially successful treatment for the disease in 20 years, and it should drive sales growth henceforth, says Value Line analyst Nira Maharaj. But the biggest opportunity (and risk) for the drug is its potential approval to treat nonalcoholic steatohepatitis (NASH), a common but serious liver condition with limited treatments. NASH represents a potential $30 billion market in annual sales globally, says Morningstar analyst Kelsey Tsai. And though many firms are vying to be the first to address the disease, Intercept’s drug is the leader in the race. There is serious concern that Intercept may lose that race, but Wedbush analyst Liana Moussatos is encouraged by Ocaliva’s success in treating NASH in recent clinical trials, one of which was stopped a year early because of better-than-expected efficacy. Moussatos’s $231 12-month price target is nearly double the current share price.
-
10 Ways to Stay Safe From Grandparent Scams and Other Fraud, Courtesy of a Financial PlannerScams are increasingly hard to detect, and anyone can be fooled, from older people to educated professionals. Here are 10 ways to avoid becoming a victim.
-
This Is How the Student Loan Bubble Is Primed to Pop, From a Student Funding ExpertFueled by easy money, inflated tuition and high default rates, the student loan bubble mirrors the 2008 subprime mortgage crisis. We could be headed for a potential financial collapse. What can we do?
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
-
If You'd Put $1,000 Into UnitedHealth Group Stock 20 Years Ago, Here's What You'd Have TodayUNH stock was a massive market beater for ages — until it wasn't.
-
If You'd Put $1,000 Into Berkshire Hathaway Stock 20 Years Ago, Here's What You'd Have TodayBerkshire Hathaway is a long-time market beater, but the easy money in BRK.B has already been made.
-
If You'd Put $1,000 Into Procter & Gamble Stock 20 Years Ago, Here's What You'd Have TodayProcter & Gamble stock is a dependable dividend grower, but a disappointing long-term holding.
-
My Three-Day Rule for Investing: And If it Applies NowStock Market I've seen a lot in my career. Here's what I see now in the stock market.
-
Is It Time to Invest in Europe?Stock Market Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
-
Why Is Warren Buffett Selling So Much Stock?Berkshire Hathaway is dumping equities, hoarding cash and making market participants nervous.
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have TodayGoogle parent Alphabet has been a market-beating machine for ages.
